Evaluation of Alpha-Therapy with Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer—the Role of Gamma Scintigraphy in Dosimetry and Pharmacokinetics

Radium-223-dichloride ((223)RaCl(2)) is a new bone-seeking calcium analogue alpha-emitter, which has obtained marketing authorization for the treatment skeletal metastases of hormone-refractory prostate cancer. The current treatment regimen is based on six consecutive doses of (223)RaCl(2) at 4 week...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Diagnostics (Basel)
Asıl Yazarlar: Kairemo, Kalevi, Joensuu, Timo, Rasulova, Nigora, Kiljunen, Timo, Kangasmäki, Aki
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: MDPI 2015
Konular:
Case Report
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4665607/
https://ncbi.nlm.nih.gov/pubmed/26854158
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/diagnostics5030358
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller